Publisher
Computers, Materials and Continua (Tech Science Press)
Reference30 articles.
1. Abkevich V, Timms KM, Hennessy BT, et al. (2012) Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776–82
2. Alsop K, Fereday S, Meldrum C, et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20;30 (21):2654–63. Erratum in: J Clin Oncol 30:4180
3. Ang JE, Gourley C, Powell CB, et al. (2013) Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 19:5485–93
4. Audeh MW, Carmichael J, Penson RT, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–51
5. Bixel K, Hays JL (2015) Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 8:127–35
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献